Basic and clinical studies of meropenem in the urological field

Kazuhiro Hata, Tadasu Takenaka, Satoshi Uno, Yoshio Nishitani, Daisuke Yamada, Toshihide Hayashi, Noriaki Ono, Masaya Tugawa, Hiromi Kumon, Hiroyuki Ohmori, Yoshikatsu Kondou, Katsuichi Nanba, Teruaki Akaeda

Research output: Contribution to journalArticle

Abstract

We studied the antibacterial activity and clinical efficacy of meropenem, a new carbapenem antibiotic, in the urological field. 1) Antibacterial activity: We measured the MICs of MEPM against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime and latamoxef. In general, the antibacterial activities of MEPM were almost equal to those of IPM but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 72.2% (13/18) for chronic complicated UTI. Bacteriologically 19 of 23 strains (82.6%) were eradicated. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, a transient elevation of GOT, GPT and LDH, and decline of Na and Cl in one case and an elevation of BUN and sCr in one case each were noted.

Original languageEnglish
Pages (from-to)607-614
Number of pages8
JournalChemotherapy
Volume40
DOIs
Publication statusPublished - 1992

Fingerprint

meropenem
Imipenem
Moxalactam
Carbapenems
Ceftazidime
Drug and Narcotic Control
Blood Urea Nitrogen
Urinary Tract Infections
Clinical Studies

Keywords

  • Meropenem

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Hata, K., Takenaka, T., Uno, S., Nishitani, Y., Yamada, D., Hayashi, T., ... Akaeda, T. (1992). Basic and clinical studies of meropenem in the urological field. Chemotherapy, 40, 607-614. https://doi.org/10.11250/chemotherapy1953.40.Supplement1_607

Basic and clinical studies of meropenem in the urological field. / Hata, Kazuhiro; Takenaka, Tadasu; Uno, Satoshi; Nishitani, Yoshio; Yamada, Daisuke; Hayashi, Toshihide; Ono, Noriaki; Tugawa, Masaya; Kumon, Hiromi; Ohmori, Hiroyuki; Kondou, Yoshikatsu; Nanba, Katsuichi; Akaeda, Teruaki.

In: Chemotherapy, Vol. 40, 1992, p. 607-614.

Research output: Contribution to journalArticle

Hata, K, Takenaka, T, Uno, S, Nishitani, Y, Yamada, D, Hayashi, T, Ono, N, Tugawa, M, Kumon, H, Ohmori, H, Kondou, Y, Nanba, K & Akaeda, T 1992, 'Basic and clinical studies of meropenem in the urological field', Chemotherapy, vol. 40, pp. 607-614. https://doi.org/10.11250/chemotherapy1953.40.Supplement1_607
Hata, Kazuhiro ; Takenaka, Tadasu ; Uno, Satoshi ; Nishitani, Yoshio ; Yamada, Daisuke ; Hayashi, Toshihide ; Ono, Noriaki ; Tugawa, Masaya ; Kumon, Hiromi ; Ohmori, Hiroyuki ; Kondou, Yoshikatsu ; Nanba, Katsuichi ; Akaeda, Teruaki. / Basic and clinical studies of meropenem in the urological field. In: Chemotherapy. 1992 ; Vol. 40. pp. 607-614.
@article{f55b1c00dda5405daa538ad2035c92e6,
title = "Basic and clinical studies of meropenem in the urological field",
abstract = "We studied the antibacterial activity and clinical efficacy of meropenem, a new carbapenem antibiotic, in the urological field. 1) Antibacterial activity: We measured the MICs of MEPM against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime and latamoxef. In general, the antibacterial activities of MEPM were almost equal to those of IPM but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 72.2{\%} (13/18) for chronic complicated UTI. Bacteriologically 19 of 23 strains (82.6{\%}) were eradicated. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, a transient elevation of GOT, GPT and LDH, and decline of Na and Cl in one case and an elevation of BUN and sCr in one case each were noted.",
keywords = "Meropenem",
author = "Kazuhiro Hata and Tadasu Takenaka and Satoshi Uno and Yoshio Nishitani and Daisuke Yamada and Toshihide Hayashi and Noriaki Ono and Masaya Tugawa and Hiromi Kumon and Hiroyuki Ohmori and Yoshikatsu Kondou and Katsuichi Nanba and Teruaki Akaeda",
year = "1992",
doi = "10.11250/chemotherapy1953.40.Supplement1_607",
language = "English",
volume = "40",
pages = "607--614",
journal = "Chemotherapy",
issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies of meropenem in the urological field

AU - Hata, Kazuhiro

AU - Takenaka, Tadasu

AU - Uno, Satoshi

AU - Nishitani, Yoshio

AU - Yamada, Daisuke

AU - Hayashi, Toshihide

AU - Ono, Noriaki

AU - Tugawa, Masaya

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Kondou, Yoshikatsu

AU - Nanba, Katsuichi

AU - Akaeda, Teruaki

PY - 1992

Y1 - 1992

N2 - We studied the antibacterial activity and clinical efficacy of meropenem, a new carbapenem antibiotic, in the urological field. 1) Antibacterial activity: We measured the MICs of MEPM against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime and latamoxef. In general, the antibacterial activities of MEPM were almost equal to those of IPM but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 72.2% (13/18) for chronic complicated UTI. Bacteriologically 19 of 23 strains (82.6%) were eradicated. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, a transient elevation of GOT, GPT and LDH, and decline of Na and Cl in one case and an elevation of BUN and sCr in one case each were noted.

AB - We studied the antibacterial activity and clinical efficacy of meropenem, a new carbapenem antibiotic, in the urological field. 1) Antibacterial activity: We measured the MICs of MEPM against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime and latamoxef. In general, the antibacterial activities of MEPM were almost equal to those of IPM but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 72.2% (13/18) for chronic complicated UTI. Bacteriologically 19 of 23 strains (82.6%) were eradicated. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, a transient elevation of GOT, GPT and LDH, and decline of Na and Cl in one case and an elevation of BUN and sCr in one case each were noted.

KW - Meropenem

UR - http://www.scopus.com/inward/record.url?scp=0026780124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026780124&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement1_607

DO - 10.11250/chemotherapy1953.40.Supplement1_607

M3 - Article

VL - 40

SP - 607

EP - 614

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -